Shareholders of Banco Bradesco S.A. have given their formal consent to a significant capital reinforcement plan, authorizing an increase of 6.67 billion Brazilian reais. This move, finalized on March 10, 2026, will be executed through the capitalization of existing legal reserves, meaning no new shares will be issued or sold. The adjustment is primarily an accounting maneuver that elevates the bank's stated share capital from 87.10 billion reais to 93.77 billion reais, pending final approval from Brazil's Central Bank.
The news had a muted immediate impact on the market. Bradesco's American Depositary Receipts (ADRs) traded on the New York Stock Exchange showed little movement, closing essentially flat at $3.88 on Wednesday. This contrasted with gains seen by peers; Itaú Unibanco's ADRs rose approximately 0.7%, while Santander Brasil's climbed around 0.8%. In Sao Paulo, Bradesco's local preferred shares had closed the previous session at 20.03 reais, marking a gain of 2.46%.
The capital decision arrives as the market continues to assess the bank's recent financial performance and forward guidance. For the full year 2025, Bradesco reported a recurring net income of 24.7 billion reais. Its return on average equity for the fourth quarter stood at 15.2%. Looking ahead to 2026, management has provided modest expectations, projecting fee income growth in a range of 3% to 5%. Concurrently, operating expenses are forecast to increase between 6% and 8%, indicating a focus on cost management will be critical to maintaining profitability.
Healthcare Unit Takes Center Stage
A potentially more transformative development is now on the horizon. Bradesco has scheduled a separate shareholder vote for March 31 to approve a major reorganization of its healthcare assets. The proposal involves transferring the bank's health insurance and related businesses to be consolidated under Odontoprev S.A., a listed dental plan specialist in which Bradesco holds a stake.
Bank leadership has positioned this strategic shift as a key future value driver. Chairman Luiz Carlos Trabuco has highlighted the healthcare unit's "scale, momentum and strategic relevance." The newly formed entity, to be called Bradsaúde, will begin operations with "zero leverage," according to designated head Carlos Marinelli. Chief Executive Marcelo Noronha has projected a substantial valuation for Bradsaúde, estimating it between 40 billion and 50 billion reais, with potential net income of 3.6 billion reais and a return on equity of 24%.
The assets slated for the spinoff, primarily from the Bradseg portfolio, carry a book value of 16.14 billion reais. Bradesco argues that housing these assets under Odontoprev will create administrative efficiencies and allow for a broader, integrated offering of health and dental services.
Execution is Key
Despite the optimistic projections, the healthcare overhaul is not yet finalized. Its implementation remains contingent on the successful March 31 shareholder vote and meeting other regulatory requirements. Furthermore, no specific timeline has been established for a subsequent follow-on offering intended to increase Bradsaúde's free float to 25%, a requirement for listing on the B3 exchange's premium Novo Mercado segment.
CEO Marcelo Noronha has remained publicly confident in the bank's strategic direction. Following the bank's February 6 earnings release, he dismissed concerns over market reaction to the updated guidance, stating he had "no concerns with that." He emphasized Bradesco's continued commitment to its transformation agenda, noting that technology spending surged 22% in 2025. On the lending front, Noronha affirmed the bank's "risk appetite is the same" but indicated a more cautious approach toward unsecured credit.
For now, Bradesco's stock appears to be in a holding pattern. The recent shareholder approvals failed to catalyze significant price movement, suggesting investors are adopting a wait-and-see approach. The market seems to be awaiting clearer signals on the execution of the capital plan and, more importantly, the progress of the ambitious healthcare restructuring before making decisive moves.
